HCW Biologics Inc. (HCWB) News
Track canonical SquawkNews coverage tagged to HCWB, HCW Biologics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
HCW Biologics Raises $1.5 Million in Private Placement of Pre-Funded Warrants; Common Warrants Pending Vote
HCW Biologics entered into a Securities Purchase Agreement with an existing institutional investor to raise approximately $1.5 million through the sale of 903,614 units at $1.6599 per unit. Each unit includes a pre-funde
NEWS | Sep 24, 2026, 01:06 PM UTC
L
HCW Biologics Inc. (HCWB) Prices $1.5M Private Placement
HCW Biologics priced a $1.5M private placement of 903,614 units to an existing stockholder, each with a pre-funded warrant and a right to receive a common warrant subject to stockholder approval.Material DetailsContext b
NEWS | Sep 24, 2026, 12:33 PM UTC
L
HCW Biologics Announces Pricing of $1.5M Private Placement
HCW Biologics Announces Pricing of $1.5M Private Placement
NEWS | Sep 24, 2026, 12:29 PM UTC
L
HCWB - HCW Biologics Announces Pricing of $1.5 Million Private Placement
HCWB - HCW Biologics Announces Pricing of $1.5 Million Private Placement
NEWS | Sep 24, 2026, 12:25 PM UTC
L
HCW Biologics removes equity-plan proposal, reschedules special meeting
The company said it will remove Proposal No. 2, an amended performance-based equity plan, from its preliminary proxy. It also said it will reschedule the special meeting.
EQUITY | Sep 10, 2026, 10:03 AM UTC
L
HCW Biologics enters exclusive distribution deal for HCW11-006
HCW Biologics entered an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006 as a reagent used to support production of highly functional human CAR-T cells.
EQUITY | Sep 08, 2026, 12:57 PM UTC
L
HCW Biologics strengthens U.S. patent estate for HCW9302 alopecia areata
HCW Biologics says it has strengthened its U.S. patent estate for HCW9302, its lead clinical-stage immunotherapeutic for alopecia areata.
EQUITY | Sep 02, 2026, 01:00 PM UTC
L
HCW Biologics highlights TGF-β trap and IL-15 fusion immunotherapy approach
HCW Biologics says its TGF-β trap and IL-15 fusion platform is a novel moiety intended to enhance immunotherapeutic activity against diseased cells.
EQUITY | Aug 25, 2026, 01:00 PM UTC
L
HCWB files S-1 for up to 1,237,364 shares
HCWB files Form S-1 covering up to 1,237,364 shares of common stock.
REGULATION | Aug 20, 2026, 07:03 PM UTC
M
HCW Biologics reports Q2 2026 business and clinical highlights
HCW Biologics (HCWB) reports second quarter 2026 business and clinical development highlights and financial results, according to TradeXchange Newsdesk.
EQUITY | Aug 14, 2026, 07:15 PM UTC
L
HCWB - HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
HCWB - HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
EQUITY | Jul 29, 2026, 01:06 PM UTC
L
HCW Biologics Regains Nasdaq Compliance After Announcing 1-For-6 Reverse Stock Split, Effective June 30
HCW Biologics Inc. (the "Company" or "HCW Biologics") (Nasdaq: HCWB ), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by ch
EQUITY | Jun 30, 2026, 12:26 PM UTC
L
HCWB Announces Reverse Split
HCW Biologics announces a 1-for-6 reverse stock split effective June 30, 2026
EQUITY | Jun 26, 2026, 12:55 PM UTC